Hence, our findings suggest that using PLGA as a vehicle to co-deliver tumor antigens (Tag) and adjuvant (CpG) activates dendritic cells with the ability for cross-priming tumor-reactive CD8+ T-cell responses via MHC class I pathways. This evidence concerns the gene CD8A and neoplasm.